Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
Status:
Completed
Trial end date:
2020-01-14
Target enrollment:
Participant gender:
Summary
Cervical cancer is one of the leading malignancies affecting women, with 311,000 deaths in
2018, most of them seen in underdeveloped countries. This neoplasm has a pre-invasive state,
such as cervical intraepithelial neoplasia (CIN), which is caused by HPV (Human
Papillomavirus) infection. The female organism most often is able to eliminate the virus,
especially in young patients. However, when the infection becomes persistent, especially for
subtypes 16 and 18, the risk of CIN developing an increased. Cytological screening programs
can efficiently and wirelessly do this. As high-grade intraepithelial lesions (CIN 2/3) are
as demonstrated by worse regression rate, only 13.3% at one year, and higher risk for
progression to invasive cancer. As CIN 2/3 need treatment, and as more therapies as they are
excisional, which theoretically are better, however, they may compromise the reproductive
future of women who are unthreatened, increasing the risk of preterm labor, premature rupture
of amniotic membranes, low weight Birth and perinatal mortality. This relationship aroused
interest in seeking alternative therapies. Decrease antiviral activity directed against HPV,
associated with a higher rate of elimination of the infection. Immediate, an agent that
stimulates like dendritic cells to producer cytokines and activates epithelial T cells.
Imiquimode, when used in vulvar neoplasias, has been shown to be effective, presenting
satisfactory results without treatment of CIN 2/3 of the uterine cervix, requiring a better
scientific compilation. Based on these data, this study aims to evaluate the efficacy of
topical immunomodulatory treatment for high-grade cervical intraepithelial lesions.